基于铜死亡相关lncRNAs构建一种新的肺鳞癌预后特征

doi:10.3760/cma.j.issn.1007-1245.2023.20.015

摘要/Abstract

摘要：

目的　基于癌症基因组图谱（TCGA）数据库建立肺鳞癌的铜死亡相关长链非编码RNAs（long non-coding RNAs，lncRNAs）风险预后模型。方法　基因及临床数据获取自TCGA数据库，铜死亡相关基因获取自铜死亡相关研究。通过共表达分析及Cox回归分析筛选lncRNAs构建预后模型。评估模型的预后价值并分析铜死亡相关lncRNAs与肺鳞癌的关系。组间差异采用Student’s t检验和Wilcoxon检验，Kaplan-Meier生存分析以Log-Rank法检验。结果　共5个lncRNAs参与构建模型。验证分析发现，高风险组患者总体生存率（OS）和无进展生存率（PFS）均较差。独立预后分析、受试者工作特征曲线（ROC）、C-指数和诺莫图显示，该模型可准确预测肺鳞癌患者的预后。进一步分析显示，铜死亡相关lncRNAs可能通过影响柠檬酸-三羧酸循环及免疫相关功能参与肺鳞癌的进展，且高风险患者免疫逃逸的潜能更大。结论　本研究构建了肺鳞癌铜死亡相关lncRNAs风险预后模型，可准确预测肺鳞癌患者预后，并与肺鳞癌多种功能关系密切。

关键词:

生物信息学, 肺鳞癌, 铜死亡, 长链非编码RNAs, 预后

Abstract:

Objective　To establish a risk prognostic model of cuproptosis associated lncRNAs in lung squamous carcinoma (LUSC) based on the Cancer Genome Atlas (TCGA) database. Methods　The gene and clinical data were obtained from the TCGA database. The cuproptosis related genes were obtained from the cuproptosis related studies. The prognosis model of lncRNAs was established by co-expression analysis and Cox regression analysis. The prognostic value of the model was evaluated. The relationship between cuproptosis associated lncRNAs and LUSC was analyzed. The differences between the groups were analyzed by Student's t and Wilcoxon tests. The Kaplan-Meier survival analysis were tested by Log-Rank. Results　A total of 5 lncRNAs participated in the construction of the model. The validation analysis found poor overall survival (OS) and progression-free survival (PFS) in high-risk patients. Independent prognostic analysis, receiver operating characteristic (ROC), C-index, and Nomo chart showed that the model could accurately predict the patients' prognosis. Further analysis showed that cuproptosis associated lncRNAs might participate in the progression of LUSC by affecting citrate-tricarboxylic acid cycling and immune-related functions, and high-risk patients had a greater potential for immune escape. Conclusions　In this study, a risk and prognosis model of LUSC cuproptosis associated lncRNAs is constructed. It can accurately predict prognosis and is closely related to multiple LUSC functions.

Key words:

Bioinformatics, Lung squamous carcinoma, Cuproptosis, LncRNA, Prognosis

张嘉琪周而乐王莎莎许映涵姜宜鑫于宁.

基于铜死亡相关lncRNAs构建一种新的肺鳞癌预后特征 [J]. 国际医药卫生导报, 2023, 29(20): 2892-2900.

Zhang Jiaqi, Zhou Erle, Wang Shasha, Xu Yinghan, Jiang Yixin, Yu Ning.

A novel prognostic feature of lung squamous carcinoma based on cuproptosis associated lncRNAs [J]. International Medicine and Health Guidance News, 2023, 29(20): 2892-2900.

参考文献

[1] Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017,389(10066):299-311. DOI: 10.1016/S0140-6736(16)30958-8.
[2] Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer[J]. Surg Pathol Clin, 2020,13(1):17-33. DOI: 10.1016/j.path.2019.11.002.
[3] Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?[J]. Lancet Oncol, 2013,14(7):e270-274. DOI: 10.1016/S1470-2045(12)70592-2.
[4] Ruiz LM, Libedinsky A, Elorza AA. Role of copper on mitochondrial function and metabolism[J]. Front Mol Biosci, 2021,8:711227. DOI: 10.3389/fmolb.2021.711227.
[5] Jiang Y, Huo Z, Qi X, et al. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes[J]. Nanomedicine (Lond), 2022,17(5):303-324. DOI: 10.2217/nnm- 2021-0374.
[6] Kaur P, Johnson A, Northcote-Smith J, et al. Immunogenic cell death of breast cancer stem cells induced by an endoplasmic reticulum-targeting copper(II) complex[J]. Chembiochem, 2020,21(24):3618-3624. DOI: 10.1002/cbic.202000553.
[7] Yu Z, Zhou R, Zhao Y, et al. Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death[J]. Cell Prolif, 2019,52(2):e12568. DOI: 10.1111/cpr.12568.
[8] Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress[J]. Nat Chem Biol, 2019,15(7):681-689. DOI: 10.1038/s41589-019-0291-9.
[9] Shanbhag VC, Gudekar N, Jasmer K, et al. Copper metabolism as a unique vulnerability in cancer[J]. Biochim Biophys Acta Mol Cell Res, 2021,1868(2):118893. DOI: 10.1016/j.bbamcr.2020.118893.
[10] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions[J]. Nat Rev Genet, 2009,10(3):155-159. DOI: 10.1038/nrg2521.
[11] Cao HL, Liu ZJ, Huang PL, et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206[J]. Eur Rev Med Pharmacol Sci, 2019,23(3):1012-1021. DOI: 10.26355/eurrev_201902_16988.
[12] Zeng J, Ma YX, Liu ZH, et al. LncRNA SNHG7 contributes to cell proliferation, invasion and prognosis of cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2019,23(21):9277-9285. DOI: 10.26355/eurrev_201911_19420.
[13] Lin J, Liao S, Liu Z, et al. LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis[J]. Cancer Biol Ther, 2021,22(3):257-266. DOI: 10.1080/15384047.2021.1883184.
[14] Zhang L, Kang W, Lu X, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway[J]. Cell Cycle, 2018,17(15):1886-1900. DOI: 10.1080/15384101.2018. 1502574.
[15] Polishchuk EV, Merolla A, Lichtmannegger J, et al. Activation of autophagy, observed in liver tissues from patients with wilson disease and from ATP7B-deficient animals, protects hepatocytes from copper-induced apoptosis[J]. Gastroenterology, 2019,156(4):1173-1189.e5. DOI: 10.1053/j.gastro.2018.11.032.
[16] Aubert L, Nandagopal N, Steinhart Z, et al. Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer[J]. Nat Commun, 2020,11(1):3701. DOI: 10.1038/s41467-020-17549-y.
[17] Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022,375(6586):1254-1261. DOI: 10.1126/science.abf0529.
[18] Dong J, Wang X, Xu C, et al. Inhibiting NLRP3 inflammasome activation prevents copper-induced neuropathology in a murine model of Wilson's disease[J]. Cell Death Dis, 2021,12(1):87. DOI: 10.1038/s41419- 021-03397-1.
[19] Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis[J]. Redox Biol, 2021,46:102122. DOI: 10.1016/j.redox.2021.102122.
[20] Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018,24(10):1550-1558. DOI: 10.1038/s41591-018-0136-1.
[21] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660.
[22] Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function[J]. J Cell Biol, 2021,220(2):e202009045. DOI: 10.1083/jcb.202009045.
[23] Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J]. Trends Biochem Sci, 2019,44(1):33-52. DOI: 10.1016/j.tibs.2018.09.012.
[24] Li J, Xia R, Liu T, et al. LncRNA-ATB promotes lung squamous carcinoma cell proliferation, migration, and invasion by targeting microRNA-590-5p/NF90 axis[J]. DNA Cell Biol, 2020,39(3):459-473. DOI: 10.1089/dna.2019.5193.
[25] Li G, Guo X. LncRNA STARD13-AS blocks lung squamous carcinoma cells growth and movement by targeting miR-1248/C3A[J]. Pulm Pharmacol Ther, 2020,64:101949. DOI: 10.1016/j.pupt.2020.101949.
[26] Koh EI, Robinson AE, Bandara N, et al. Copper import in Escherichia coli by the yersiniabactin metallophore system[J]. Nat Chem Biol, 2017,13(9):1016-1021. DOI: 10.1038/nchembio.2441.
[27] Li Y, Yang J, Zhang Q, et al. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma[J]. Oncogene, 2022,41(27):3539-3553. DOI: 10.1038/s41388-022-02364-0.
[28] Zhang Y, Dai J, Huang W, et al. Identification of a competing endogenous RNA network related to immune signature in clear cell renal cell carcinoma[J]. Aging (Albany NY), 2021,13(24):25980-26002. DOI: 10.18632/aging.203784.
[29] Filippova EA, Fridman MV, Burdennyy AM, et al. Long noncoding RNA GAS5 in breast cancer: epigenetic mechanisms and biological functions[J]. Int J Mol Sci, 2021,22(13):6810. DOI: 10.3390/ijms22136810.
[30] Li J, Yang C, Li Y, et al. LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation[J]. Biosci Rep, 2018,38(2):BSR20171150. DOI: 10.1042/BSR20171150.
[31] Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3[J]. Mol Cancer, 2019,18(1):143. DOI: 10.1186/s12943-019-1079-y.
[32] Zhu L, Zhou D, Guo T, et al. LncRNA GAS5 inhibits Invasion and migration of lung cancer through influencing EMT process[J]. J Cancer, 2021,12(11):3291-3298. DOI: 10.7150/jca.56218.
[33] Di Franco S, Turdo A, Todaro M, et al. Role of type I and II interferons in colorectal cancer and melanoma[J]. Front Immunol, 2017,8:878. DOI: 10.3389/fimmu.2017.00878.
[34] Sivori S, Pende D, Quatrini L, et al. NK cells and ILCs in tumor immunotherapy[J]. Mol Aspects Med, 2021,80:100870. DOI: 10.1016/j.mam.2020.100870.
[35] Jongsma MLM, Guarda G, Spaapen RM. The regulatory network behind MHC class I expression[J]. Mol Immunol, 2019,113:16-21. DOI: 10.1016/j.molimm.2017.12.005.
[36] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011,331(6024):1565-1570. DOI: 10.1126/science.1203486.